SG10201912497WA - A blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings - Google Patents

A blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings

Info

Publication number
SG10201912497WA
SG10201912497WA SG10201912497WA SG10201912497WA SG10201912497WA SG 10201912497W A SG10201912497W A SG 10201912497WA SG 10201912497W A SG10201912497W A SG 10201912497WA SG 10201912497W A SG10201912497W A SG 10201912497WA SG 10201912497W A SG10201912497W A SG 10201912497WA
Authority
SG
Singapore
Prior art keywords
bleedings
prophylaxis
treatment
blood coagulation
coagulation factor
Prior art date
Application number
SG10201912497WA
Other languages
English (en)
Inventor
Eva Herzog
Gerald Hochleitner
Oliver Grottke
Original Assignee
Csl Behring Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Gmbh filed Critical Csl Behring Gmbh
Publication of SG10201912497WA publication Critical patent/SG10201912497WA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727Heparin; Heparan
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38Albumins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38Albumins
    • A61K38/385Serum albumin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4833Thrombin (3.4.21.5)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21005Thrombin (3.4.21.5)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21021Coagulation factor VIIa (3.4.21.21)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21022Coagulation factor IXa (3.4.21.22)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21038Coagulation factor XIIa (3.4.21.38)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG10201912497WA 2017-02-09 2018-02-09 A blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings SG10201912497WA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17155420 2017-02-09

Publications (1)

Publication Number Publication Date
SG10201912497WA true SG10201912497WA (en) 2020-02-27

Family

ID=58016586

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201912497WA SG10201912497WA (en) 2017-02-09 2018-02-09 A blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings

Country Status (13)

Country Link
US (1) US11744880B2 (https=)
EP (1) EP3579857B1 (https=)
JP (1) JP7227905B2 (https=)
KR (1) KR102658958B1 (https=)
CN (1) CN110114074B (https=)
AU (1) AU2018217375B2 (https=)
BR (1) BR112019012772A2 (https=)
CA (1) CA3046406C (https=)
DK (1) DK3579857T3 (https=)
ES (1) ES2913934T3 (https=)
PL (1) PL3579857T3 (https=)
SG (1) SG10201912497WA (https=)
WO (1) WO2018146235A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021201950A1 (en) * 2020-04-04 2021-10-07 The Board Of Regents Of The University Of Texas System Method for reducing the occurrence of thrombosis or thromboembolism
CN113929741A (zh) * 2020-06-29 2022-01-14 首都医科大学 华法林-4-O-乙酰-Gly-Pro-Arg-Pro-AA1及其合成、活性和应用
WO2026048976A1 (ja) * 2024-08-30 2026-03-05 Kmバイオロジクス株式会社 血液凝固第x因子を含む安定な医薬組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663164A (en) * 1980-01-28 1987-05-05 Baxter Travenol Laboratories, Inc. Aqueous compositions for treating blood clotting factor inhibitors
DE3101752A1 (de) 1981-01-21 1982-08-26 Behringwerke Ag, 3550 Marburg "verfahren zur reinigung der blutgerinnungsfaktoren ii, vii, ix und/oder x und danach hergestellte praeparationen"
DE3336631A1 (de) * 1983-10-08 1985-04-18 Behringwerke Ag, 3550 Marburg Verfahren zur pasteurisierung von plasma oder von konzentraten der blutgerinnungsfaktoren ii, vii, ix und x
DE3622642A1 (de) * 1986-07-05 1988-01-14 Behringwerke Ag Einkomponenten-gewebekleber sowie verfahren zu seiner herstellung
SI0796623T1 (en) 1996-03-20 2005-10-31 Baxter Aktiengesellschaft Pharmaceutical preparation for the treatment of blood coagulation disorders
AT409334B (de) * 1997-09-19 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren
WO2004068109A2 (en) * 2003-01-27 2004-08-12 Harvest Technologies Inc Autologous or homologous coagulant produced from anticoagulated whole blood
FR2946348B1 (fr) * 2009-06-05 2011-08-05 Lab Francais Du Fractionnement Procede de preparation d'une composition de complexe prothrombique a haut degre de purete
CA2812888A1 (en) 2010-10-06 2012-04-12 Medimmune Limited Factor ii and fibrinogen for treatment of haemostatic disorders
TWI653047B (zh) 2014-03-14 2019-03-11 百特製藥公司 用於在出血性病症的治療中促進止血的人類凝血酶原及活化因子x的組成物
WO2016198351A1 (en) * 2015-06-10 2016-12-15 Evonik Röhm Gmbh Process for preparing a powder comprising a human coagulation factor protein and a lactic acid polymer

Also Published As

Publication number Publication date
JP7227905B2 (ja) 2023-02-22
ES2913934T3 (es) 2022-06-06
EP3579857B1 (en) 2022-04-06
CA3046406C (en) 2024-01-30
AU2018217375B2 (en) 2024-04-18
AU2018217375A1 (en) 2019-06-27
WO2018146235A8 (en) 2019-05-09
BR112019012772A2 (pt) 2019-12-10
US11744880B2 (en) 2023-09-05
DK3579857T3 (da) 2022-06-07
CN110114074B (zh) 2024-05-28
CN110114074A (zh) 2019-08-09
JP2020506880A (ja) 2020-03-05
KR102658958B1 (ko) 2024-04-22
EP3579857A1 (en) 2019-12-18
PL3579857T3 (pl) 2022-07-25
KR20190111912A (ko) 2019-10-02
CA3046406A1 (en) 2018-08-16
WO2018146235A1 (en) 2018-08-16
US20190351028A1 (en) 2019-11-21

Similar Documents

Publication Publication Date Title
PL3577135T3 (pl) Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5
AU201810677S (en) Skin treatment article
ZA201700459B (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
AU201714140S (en) Skin treatment article
AU201714143S (en) Skin treatment article
SI3672954T1 (sl) Spojine, njihove soli in njihova uporaba za zdravljenje bolezni
AU201810686S (en) Skin treatment article
LT3377637T (lt) Kompozicijos, skirtos panaudoti žaizdų, sutrikimų ir odos ligų gydymo būduose
PL3676285T3 (pl) Szczepionka do stosowania w profilaktyce i/lub leczeniu choroby
GB2542155B (en) Use of cannabidiol in the treatment of mental disorders
AU201810689S (en) Skin treatment article
IL254142B (en) Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent
AU201810683S (en) Skin treatment article
AU201714141S (en) Skin treatment article
AU201810685S (en) Skin treatment article
AU201810687S (en) Skin treatment article
HUE044905T2 (hu) Halak takarmánya és annak alkalmazása a vérzéses szamár szindróma (HSS) megelõzésében és kezelésében a lazacfélékben
PT3307277T (pt) Oligonucleótidos de cadeia simples para utilização no tratamento médico de distúrbios da pele
AU201810676S (en) Skin treatment article
SG10201912497WA (en) A blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings
ZA201807692B (en) New use of product for skin treatment
GB201519557D0 (en) Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions
AU201810675S (en) Skin treatment article
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
IL248428B (en) 3,1-propanedisulfonic acid or its pharmaceutically acceptable salt for use in the treatment of sarcoidosis